Hematology & Transfusion International Journal

Fifth International Symposium on Myelodysplastic Syndromes.

Economics of pathogen inactivation technology for platelet concentrates in Japan.

Residual risk of transmitting recognized and emerging blood-borne pathogens via blood transfusion in Japan persists despite advances in blood safety screening. The INTERCEPT Blood System (IBS) for platelets was developed to inactivate a broad spectrum of pathogens to reduce the risk of transfusion-transmitted infections. In this study we assessed the economic impact of the IBS on platelet trans...

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The ...

Five years of implementation of guidelines in hematology and transfusion medicine in Brazil

Conflicts of interest n 2009, the Associação Brasileira de Hematologia e emoterapia (ABHH) started to participate in an imporant mission proposed by the Associação Médica Brasileira AMB) and the Conselho Federal de Medicina named “Project uidelines”. This project had already been adopted by some ther specialties. It aims to determine diagnostic, monitoring, revention and therapeutic practices a...

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes

Many patients with bone marrow failure syndromes need frequent transfusions of red blood cells, and most of them eventually suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat transfusion-induced iron overload is iron chelating therapy. However, most patients have not been treated effectively because daily/continuous administration of deferoxamine is dif...

Professor Pedro Clóvis Junqueira

Clovis Pedro Junqueira, considered a living legend in transfusion medicine in Brazil died on October 2, 2011, at the age of 94 years. Until about 1 or 2 years ago, Professor Junqueira was still active, receiving honors and being interviewed and consulted about the future of hemotherapy in Brazil. He was seen in the library that bears his name at the headquarters of the Brazilian Society of Hema...